The mission of CDx Diagnostics® is to provide clinicians with easily implemented, cost-effective tools to preempt cancer through enhanced detection of precancerous cellular changes. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost-effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Routine clinical use of CDx testing has already detected thousands of precancerous cells that would otherwise have been missed in time for effective endoscopic treatment and application of the CDx diagnostic platform to prevent cancers of the bile duct, stomach, and IBD affected colon is currently in progress. About WATS3D WATS3D addresses the major inadequacies inherent in current random forceps biopsy testing of the esophagus. In just a few minutes, endoscopists can easily obtain a wide area, full-thickness transepithelial specimen for computer-assisted 3D laboratory analysis prior to diagnosis by any WATS3D certified pathologist. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both Barrett’s esophagus and esophageal dysplasia. The high sensitivity and inter-observer agreement of WATS3D is due to the larger tissue area sampled, and the proprietary 3-Dimensional computer imaging system that is based on an artificial intelligence algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.wats3d.com.
View Top Employees from CDx Diagnostics®Website | http://www.cdxdiagnostics.com |
Revenue | $21.2 million |
Funding | $27 million |
Employees | 133 (133 on RocketReach) |
Founded | 2010 |
Address | 2 Executive Blvd Ste 102, Suffern, New York 10901, US |
Phone | (845) 777-7000 |
Technologies |
JavaScript,
HTML,
Twitter
+48 more
(view full list)
|
Industry | Biotechnology, Medical and Diagnostic Laboratories, Hospitals & Clinics, Biopharma, Laboratory Services (Healthcare), Detection of Oral Dysplasia & Cancer, Healthcare, Detection of Esophoageal Dysplasia & Cancer, Health Care, Early Detection of Barrett's Esophagus, Science and Engineering, Detection of Laryngeal Dysplasia & Cancer, Prevention of Oral Cancer, Prevention of Esophageal Cancer |
Web Rank | 8 Million |
Keywords | Cancer Diagnosis |
Competitors | Exagen Diagnostics Inc, Genova Diagnostics, Great Basin Scientific, Inc., Helix, Personalis, Inc. |
SIC | SIC Code 8071 Companies, SIC Code 807 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 62 Companies, NAICS Code 621 Companies |
Looking for a particular CDx Diagnostics® employee's phone or email?
The CDx Diagnostics® annual revenue was $21.2 million in 2024.
Thomas Bartel is the Executive Vice President of Sales of CDx Diagnostics®.
133 people are employed at CDx Diagnostics®.
CDx Diagnostics® is based in Suffern, New York.
The NAICS codes for CDx Diagnostics® are [62, 621].
The SIC codes for CDx Diagnostics® are [8071, 807, 80].